New Clinical And Nonclinical Data On Viaskin® Will Be Presented At The 2015 EAACI Congress
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical stage specialty biopharmaceutical company, today announced that new clinical and nonclinical data on Viaskin® via Epicutaneous Immunotherapy (EPIT®) will be presented during 2015 European Academy of Allergy and Clinical Immunology, (EAACI) Annual Meeting in Barcelona, Spain, June 6-10, 2015. Presentations will include additional post-hoc results from the Phase 2b trial of Viaskin® Peanut in peanut allergic patients, as well as key nonclinical data on EPIT’s mechanism of action.
The abstracts will also be published in the June 2015 supplement of the European journal of allergy and clinical immunology, Allergy.
Title- Epicutaneous Immunotherapy (EPIT®) for peanut allergy
Date - June 9 - 1:30 pm to 3:00 pm
Presenter - Pr. Hugh A. Sampson from Kurt Hirschhorn Professor of Pediatrics, Director of the Jaffe
Food Allergy Institute and Dean of Translational Biomedical Science at The Mount Sinai Medical Center in New York (USA)
Session Name - Beyond Oral Immunotherapy (OIT) in food allergy
Session - SYM 47
Type of Session - Satellite Symposium
Location - Auditorium
Title - Deciphering the dose-response effect of peanut Epicutaneous Immunotherapy (EPIT®) in peanut allergic subjects
Date June 7 - 10:30 am to 12:00 pm
Presenter - Pr. Christophe Dupont, Head of the Pediatric-Gastroenterology Ambulatory Department at Necker Hospital, Paris, France
Session - PDS 1 New clinical data in AIT - Abstract: 1746
Type of Session - Poster Discussion Session
Location - Poster Discussion Zone 1
Title - Epicutaneous immunotherapy to a specific allergen prevents from sensitization and anaphylaxis to further allergens: the role of regulatory T-cells
Date- June 7 - 3:30 pm to 5:00 pm
Presenter - Dr. Lucie Mondoulet, Director of Research at DBV Technologies
Session Name - Control of vaccines for AIT Bagneux, France, Wednesday, April 15, 2015
Session Poster Number: 1159, Session Number: OAS 13
Type of Session - Oral Abstract Session
Location - Room 116
Title - Epicutaneous immunotherapy leads to sustainable GATA-3 hypermethylation and Foxp3 hypomethylation in peanut sensitized mice
Date - June 8 - 3:45 pm to 5:15 pm
Presenter - Dr. Lucie Mondoulet, Director of Research at DBV Technologies
Session Name - Mechanisms of AIT, Session Number: 1145, Session Number: PDS 19
Type of Session- Poster Discussion Session
Location - Poster Discussion Zone 1
Title - Larger homing receptor expression on Tregs suggests increased efficacy of epicutaneous compared to oral or sublingual immunotherapy for the treatment of food allergy
Date - June 8 - 3:45 pm to 5:15 pm
Presenter - Dr. Vincent Dioszeghy, Scientist at DBV Technologies
Session Name - Mechanisms of AIT, Session Number: 1073, Session Number: PDS 19
Type of Session - Poster Discussion Session
Location - Poster Discussion Zone 1
About DBV Technologies
DBV Technologies is developing Viaskin®, an innovative new approach to the treatment of allergies – a major
public health issue that has been increasing in prevalence. DBV Technologies, incorporated in France in 2002,
has developed a proprietary, worldwide-patented technology for administering an allergen to intact skin while
avoiding transfer to the blood, and thus considerably lowering the risk of a systemic, allergic reaction in the
event of accidental exposure. DBV Technologies is focusing on food allergies, including milk and peanut, for
which there are currently no effective treatments. DBV Technologies has designed two products candidates:
Viaskin® Peanut and Viaskin® Milk. The clinical development program for Viaskin® Peanut has received Fast
Track designation from the US Food and Drug Administration.
DBV Technologies shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345)
and on the Nasdaq Stock Market in the form of American Depositary Shares (each representing one-half of
one ordinary share) (Ticker: DBVT). For more information on DBV Technologies, please visit our website:
www.dbv-technologies.com.
Forward Looking Statements
This press release contains forward-looking statements, including statements about the safety and efficacy of
Epicutenaous Immunotherapy (EPIT) via Viaskin, including the potential to prevent sensitizations in other
allergens, the potential to induce a sustained protection effect and the potential to influence the natural
history of allergy. These forward-looking statements are not promises or guarantees and involve substantial
risks and uncertainties. In particular it should be noted that these data are preclinical in nature and have not
been demonstrated in human subjects. The company’s product candidates have not been approved for sale in
any jurisdiction. Among the factors that could cause actual results to differ materially from those described or
projected herein include uncertainties associated generally with research and development, clinical trials and
related regulatory reviews and approvals, the risk that historical preclinical results may not be predictive of
future clinical trial results, and the risk that historical clinical trial results may not be predictive of future trial
results. A further list and description of these risks, uncertainties and other risks can be found in the
Company’s regulatory filings with the French Autorité des Marchés Financiers, the Company’s Securities and
Exchange Commission filings and reports, including in the Company’s prospectus filed with the SEC on October
22, 2014 and future filings and reports by the Company. Existing and prospective investors are cautioned not
to place undue reliance on these forward-looking statements, which speak only as of the date hereof. DBV
Technologies undertakes no obligation to update or revise the information contained in this Press Release,
whether as a result of new information, future events or circumstances or otherwise.